Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
975 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03653507 | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).(GLOW) | active not recruiting | Phase 3 | 507 | Astellas Pharma Global Development, Inc.INDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT03734029 | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | completed | Phase 3 | 557 | Daiichi Sankyo |
| 20 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT03833167 | Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | terminated | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 28, 2026 | clinicaltrials |
| NCT04487080 | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer(MARIPOSA) | active not recruiting | Phase 3 | 1,074 | Janssen Research & Development, LLCINDUSTRY | 28 | Sep 28, 2026 | clinicaltrials |
| NCT04497844 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)(AMPLITUDE) | active not recruiting | Phase 3 | 696 | Janssen Research & Development, LLCINDUSTRY | 33 | Sep 28, 2026 | clinicaltrials |
| NCT04711252 | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease(SERENA-4) | active not recruiting | Phase 3 | 1,371 | AstraZenecaINDUSTRY | 27 | Sep 28, 2026 | clinicaltrials |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | active not recruiting | Phase 3 | 461 | Mirati Therapeutics Inc.INDUSTRY | 32 | Sep 28, 2026 | clinicaltrials |
| NCT04988295 | A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure(MARIPOSA-2) | active not recruiting | Phase 3 | 776 | Janssen Research & Development, LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT05100862 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma(MAHOGANY) | active not recruiting | Phase 3 | 799 | BeOne MedicinesINDUSTRY | 28 | Sep 28, 2026 | clinicaltrials |
| NCT05388669 | A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer(PALOMA-3) | active not recruiting | Phase 3 | 418 | Janssen Research & Development, LLCINDUSTRY | 20 | Sep 28, 2026 | clinicaltrials |
| NCT06961006 | A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | recruiting | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 28, 2026 | clinicaltrials |
| NCT07099898 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] | recruiting | Phase 3 | 420 | GlaxoSmithKlineINDUSTRY | 25 | Sep 28, 2026 | clinicaltrials |
| NCT07293754 | An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors(RaPTR-101) | recruiting | Phase 1 / Phase 2 | 150 | Repertoire Immune MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT03390504 | A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations(THOR) | active not recruiting | Phase 3 | 629 | Janssen Research & Development, LLCINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT03748641 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer(MAGNITUDE) | active not recruiting | Phase 3 | 765 | Janssen Research & Development, LLCINDUSTRY | 29 | Sep 25, 2026 | clinicaltrials |
| NCT04557059 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer(PRIMORDIUM) | active not recruiting | Phase 3 | 691 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT04640623 | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy(SunRISe-1) | active not recruiting | Phase 2 | 220 | Janssen Research & Development, LLCINDUSTRY | 16 | Sep 25, 2026 | clinicaltrials |
| NCT04658862 | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder(SunRISe-2) | active not recruiting | Phase 3 | 518 | Janssen Research & Development, LLCINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT04892173 | JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | recruiting | Phase 3 | 500 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy(CARTITUDE-5) | active not recruiting | Phase 3 | 743 | Janssen Research & Development, LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT05023980 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-313) | active not recruiting | Phase 3 | 282 | Loxo Oncology, Inc.INDUSTRY | 20 | Sep 25, 2026 | clinicaltrials |
| NCT05132075 | Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer(KontRASt-02) | active not recruiting | Phase 3 | 95 | Novartis PharmaceuticalsINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT05160584 | A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma(MoMMent) | recruiting | — | 300 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 12 | Sep 25, 2026 | clinicaltrials |
| NCT05287113 | Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 176 | Incyte Biosciences International SàrlINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT05552222 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma(MajesTEC-7) | recruiting | Phase 3 | 1,590 | Janssen Research & Development, LLCINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT05714202 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)(SunRISe-3) | active not recruiting | Phase 3 | 1,135 | Janssen Research & Development, LLCINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | recruiting | Phase 3 | 1,314 | Merck Sharp & Dohme LLCINDUSTRY | 39 | Sep 25, 2026 | clinicaltrials |
| NCT06170788 | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)(TroFuse-007) | recruiting | Phase 3 | 614 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT06252753 | Observational Study Protocol: LIVER-R(LIVER-R) | recruiting | — | 4,000 | AstraZenecaINDUSTRY | 22 | Sep 25, 2026 | clinicaltrials |
| NCT06284122 | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5(MorningLyte) | active not recruiting | Phase 3 | 790 | The Lymphoma Academic Research OrganisationOTHER | 7 | Sep 25, 2026 | clinicaltrials |
| NCT06312137 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)(TroFuse-019) | recruiting | Phase 3 | 780 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 25, 2026 | clinicaltrials |
| NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | recruiting | Phase 3 | 1,530 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 25, 2026 | clinicaltrials |
| NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) | active not recruiting | Phase 3 | 621 | Merus B.V.INDUSTRY | 24 | Sep 25, 2026 | clinicaltrials |
| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | active not recruiting | Phase 3 | 699 | Merus B.V.INDUSTRY | 28 | Sep 25, 2026 | clinicaltrials |
| NCT06667076 | A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)(COPERNICUS) | recruiting | Phase 2 | 480 | Janssen Research & Development, LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT06852222 | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)(cAMeLot-2) | recruiting | Phase 3 | 600 | Janssen Research & Development, LLCINDUSTRY | 25 | Sep 25, 2026 | clinicaltrials |
| NCT06868277 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer(ARTEMIDELung04) | recruiting | Phase 3 | 830 | AstraZenecaINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | recruiting | Phase 3 | 2,400 | Merck Sharp & Dohme LLCINDUSTRY | 40 | Sep 25, 2026 | clinicaltrials |
| NCT07276399 | A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer(OrigAMI-5) | recruiting | Phase 3 | 500 | Janssen Research & Development, LLCINDUSTRY | 22 | Sep 25, 2026 | clinicaltrials |
| NCT04624204 | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | active not recruiting | Phase 3 | 672 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Sep 24, 2026 | clinicaltrials |
| NCT05152147 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers(HERIZON-GEA-01) | active not recruiting | Phase 3 | 920 | Jazz PharmaceuticalsINDUSTRY | 33 | Sep 24, 2026 | clinicaltrials |
| NCT05215340 | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations(TROPION-Lung08) | active not recruiting | Phase 3 | 740 | Daiichi SankyoINDUSTRY | 28 | Sep 24, 2026 | clinicaltrials |
| NCT06062420 | A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 | active not recruiting | Phase 2 | 316 | GlaxoSmithKlineINDUSTRY | 20 | Sep 24, 2026 | clinicaltrials |
Data updated 20 hours agoSource updated unknownsource: clinicaltrials